Sign Out
Epirubicin Hydrochloride has produced responses in a wide range of neoplastic conditions including breast, ovarian, gastric, lung and colorectal carcinomas, malignant lymphomas, leukaemias and multiple myeloma.
Intravesical administration of Epirubicin hydrochloride has been found to be beneficial in the treatment of superficial bladder cancer, carcinoma-in-situ prophylaxis of recurrences after transurethral resection, superficial bladder cancer and advanced metastatic soft tissue sarcoma.
